CN110368487A - A kind of functional nutrient food improving cardiovascular and cerebrovascular health status - Google Patents
A kind of functional nutrient food improving cardiovascular and cerebrovascular health status Download PDFInfo
- Publication number
- CN110368487A CN110368487A CN201910733483.9A CN201910733483A CN110368487A CN 110368487 A CN110368487 A CN 110368487A CN 201910733483 A CN201910733483 A CN 201910733483A CN 110368487 A CN110368487 A CN 110368487A
- Authority
- CN
- China
- Prior art keywords
- parts
- cardiovascular
- nutrient food
- functional nutrient
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 30
- 235000013305 food Nutrition 0.000 title claims abstract description 19
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 18
- 230000003862 health status Effects 0.000 title claims description 5
- 239000002994 raw material Substances 0.000 claims abstract description 11
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 10
- 239000000843 powder Substances 0.000 claims abstract description 10
- 244000068988 Glycine max Species 0.000 claims abstract description 8
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims abstract description 8
- 102000007625 Hirudins Human genes 0.000 claims abstract description 6
- 108010007267 Hirudins Proteins 0.000 claims abstract description 6
- 241000237636 Pheretima Species 0.000 claims abstract description 6
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims abstract description 6
- 229940006607 hirudin Drugs 0.000 claims abstract description 6
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 5
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 5
- 229920001353 Dextrin Polymers 0.000 claims abstract description 5
- 239000004375 Dextrin Substances 0.000 claims abstract description 5
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 5
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 5
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 5
- 102000003797 Neuropeptides Human genes 0.000 claims abstract description 5
- 108090000189 Neuropeptides Proteins 0.000 claims abstract description 5
- 235000019425 dextrin Nutrition 0.000 claims abstract description 5
- 229960000304 folic acid Drugs 0.000 claims abstract description 5
- 235000019152 folic acid Nutrition 0.000 claims abstract description 5
- 239000011724 folic acid Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 229940026314 red yeast rice Drugs 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 235000013339 cereals Nutrition 0.000 claims abstract description 4
- 229920002472 Starch Polymers 0.000 claims abstract description 3
- 235000013361 beverage Nutrition 0.000 claims abstract description 3
- 229940100688 oral solution Drugs 0.000 claims abstract description 3
- 229920001592 potato starch Polymers 0.000 claims abstract description 3
- 235000019698 starch Nutrition 0.000 claims abstract description 3
- 239000008107 starch Substances 0.000 claims abstract description 3
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 25
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 12
- 230000036541 health Effects 0.000 abstract description 9
- 230000009467 reduction Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000003449 preventive effect Effects 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 208000021479 Cardiovascular injury Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 241001495098 Lumbricus rubellus Species 0.000 description 1
- 102000002568 Multienzyme Complexes Human genes 0.000 description 1
- 108010093369 Multienzyme Complexes Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001194 anti-hemostatic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008455 cerebrovascular function Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 108010070324 lumbrokinase Proteins 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Abstract
The present invention provides the functional nutrient food of a kind of adjusting cardiovascular and cerebrovascular health and reduction cardiovascular and cerebrovascular disease risk.Using following technical scheme: the effective active composition raw material comprising following parts by weight: 20 parts of freeze dry powder of fermented soybean, 15 parts of gadol extract, 5 parts of hirudin, 3 parts of pheretima.2 parts of folic acid, 3 parts of Radix Salviae Miltiorrhizae, 5 parts of wilsonii, 5 parts of ginkgo, 2 parts of neuropeptide, 5 parts of red yeast rice, 8 parts of safflower.The auxiliary material of 10%~20% parts by weight of medicinal material total weight is accounted for, the auxiliary material can be cereal starch or potato starch or dextrin.Tablet, capsule, oral solution or beverage is made using routine fashion in each raw material.Functional nutrient food formula design of the present invention is rationally ingenious, it is mutually cooperateed between each component, preventive and therapeutic action of the maximum ultimate attainment performance to cardiovascular and cerebrovascular disease, and the product safety, it is efficient high, have no toxic side effect, be a kind of optimal functional nutrient food for preventing and treating cardiovascular and cerebrovascular disease.
Description
Technical field
The present invention relates to a kind of nutraceutical, and in particular to one kind can improve the functional battalion of cardiovascular and cerebrovascular health status
Support food.
Background technique
Cardiovascular and cerebrovascular disease is exactly that cardiovascular and cerebrovascular disease are referred to as, and common disease has heart disease, apoplexy, old age
Dementia, parkinsonism, hyperlipidemia, hyperglycemia and hypertension etc..It is strong that cardiovascular and cerebrovascular disease is that one kind seriously threatens the mankind
The common disease of health, it has the characteristics that disease incidence height, disability rate height, death rate height, high recurrence rate, complication are more.Currently, China
Patients with Cardiovascular/Cerebrovascular Diseases alreadys exceed 300,000,000 people, dies of nearly 3,000,000 people of cardiovascular and cerebrovascular disease every year, and it is annual total dead to account for China
The 51% of the cause of disease.Cardiovascular and cerebrovascular disease drastically influences the general level of the health of our people, is that the previous great society of mesh is medical and strong
Kang Wenti.
For the cause of disease that cardiovascular and cerebrovascular disease occurs, researcher proposes the scheme for preventing and treating and combining, as drug is controlled
It treats, keep on a diet, the methods of mode of making the life better.Medicinal treatment is although quick, but side effect is big, is easy recurrence, can be to people
Body cause further to injure；And the effect of food therapy or mode of making the life better is also unobvious and the period is longer.Domestic and international mesh
Although the preceding drug and health care product for having many treatment cardiovascular and cerebrovascular diseases, its validity and safety are uncertain, and there are no one
Kind special efficacy, safe, the natural functional nutrient food for adjusting cardiovascular and cerebrovascular health and reducing cardiovascular and cerebrovascular disease risk.
Summary of the invention
The purpose of the present invention is to provide the functions of a kind of adjusting cardiovascular and cerebrovascular health and reduction cardiovascular and cerebrovascular disease risk
Property nutraceutical.Functional nutrient food formula design is rationally ingenious, mutually cooperates between each component, maximum ultimate attainment performance pair
The preventive and therapeutic action of cardiovascular and cerebrovascular disease, and the product safety, it is efficient high, have no toxic side effect, be a kind of prevention and control
Treat the optimal functional nutrient food of cardiovascular and cerebrovascular disease.
The invention adopts the following technical scheme:
A kind of functional nutrient food improving cardiovascular and cerebrovascular health status, it includes the effective active composition original of following parts by weight
Material: 20 parts of freeze dry powder of fermented soybean, 15 parts of gadol extract, 5 parts of hirudin, 3 parts of pheretima.
It also includes the effective active composition raw material of following parts by weight: 2 parts of folic acid, 3 parts of Radix Salviae Miltiorrhizae, and 5 parts of wilsonii, ginkgo 5
Part, 2 parts of neuropeptide, 5 parts of red yeast rice, 8 parts of safflower.
It include account for medicinal material total weight 10%~20% parts by weight auxiliary material, the auxiliary material can be cereal starch,
Or potato starch or dextrin.
Tablet, capsule, oral solution or beverage is made using routine fashion in each raw material.
Compound basis of the invention is as follows:
Freeze dry powder of fermented soybean is the natto of solid fermentation, after subzero 40 degrees Celsius are freezed, through vacuum dehumidifying lyophilization, powder
It is broken, become freeze dry powder of fermented soybean.Freeze dry powder of fermented soybean can dissolve thrombus, repair impaired blood cell, vascular cell, be effectively improved
Coronary heart disease, hypertension, artery sclerosis, apoplexy, varication.It is very significant for cardiovascular health-care effect.
Gadol extract is brown or brown-red powder, and gas is fragrant and sweet, bitter and puckery flavor, is slightly soluble in water or ethyl alcohol.Root of kirilow rhodiola mentions
It takes object that can mitigate cardiovascular injury and the disorder of due to pressure, prevents under affective state because of heart that ambient pressure is secondary
Convergent force decline, plays the effect of protection cardiac muscle.
Hirudin energy efficient anticoagulation, antithrombus formation, and prevent the coagulation factor activation of catalyzed by thrombin and blood small
The further blood stasis phenomenon such as plate reaction.In addition, it can also inhibit the fibroblastic proliferation and fibrin ferment pair of thrombin induction
The stimulation of endothelial cell.Compared with heparin, not only dosage is few for it, will not cause bleeding, also not dependent on endogenous co-factor;
And heparin then has the danger to cause bleeding, Antithrombin III is often reduced in the pathogenic process of disseminated intravascular coagulation, this
The curative effect of heparin will be limited, preferable effect is had using leech.
Pheretima contains Lumbrokinase, is a kind of multienzyme complex by extracting in red red earthworm body, the function with protein hydrolysate
Effect, to treat ischemic cerebrovascular disease.
Folic acid is the manufacture indispensable substance of red blood cell.Patients with geriatric cardiovascular and cerebrovascular diseases is come, hematopoiesis function is sound to be conducive to the heart
Cerebrovascular health.
Radix Salviae Miltiorrhizae reinforces myocardial contractive power, improves cardiac function, does not increase myocardial oxygen consumption.
Wilsonii can bowl spares, strengthening the essence, Qiang Yizhi, raise heart spleen, it is weary for the heart qi deficiency caused by heart disease have good effect.
Ginkgo contains anti-platelet activating factor, can anti-Hemostatic Oral Liquid agglutination, improve blood circulation, the shape of anti-tampon
At can expand blood vessel containing flavones, eliminate free radical, prevent artery sclerosis, prevent myocardial infarction.
Neuropeptide can enhance vessel retraction, moreover it is possible to lead to reangiostenosis.Primary vascular smooth muscle of the NPY in vitro culture
Cell has apparent proliferation function.
Effective ingredient is the competitive inhibitor of HMG-CoA reductase in red yeast rice, to just block synthetic cholesterol
Access plays the role for the treatment of and prevention cardiovascular and cerebrovascular disease.
Safflower has excitation to breathing, under conditions of normobaric hypoxia, it is possible to increase the production quantity of pyruvic acid improves the heart
Lactic acid dehydrogenase activity in myocyte improves the hypoxia-bearing capability of heart, one so as to enhance intracellular oxygen metabolism function
Determine to weaken damage of the strenuous exercise to cardiac muscle cell in degree, has certain protective role to heart.
Although each ingredient plays the role of different degrees of reduction cardiovascular and cerebrovascular disease probability of happening in inventive formulation,
Every kind of component emphasis and mechanism of action difference, synergistic effect is played with the use of rear each component, and raw material availability is high,
It is significant to the prevention and therapeutic effect of cardiovascular and cerebrovascular disease.This raw materials used formula is commercially available conventional purchase raw material, safe nothing
Toxic side effect, it is safe that the toxicological test of this pharmaceutical formulation, which also indicates that,.
The beneficial effects of the present invention are: health caring product prescription of the present invention designs reasonable benefit/risk, mutually act synergistically between each component,
The generation of cardiovascular and cerebrovascular disease can effectively be prevented, improve blood cerebrovascular function, and the product safety, efficient high, nontoxic pair
Effect is a kind of good functional nutrient food for preventing and treating cardiovascular and cerebrovascular disease.
Specific embodiment
The contents of the present invention are described in further detail combined with specific embodiments below.
Embodiment 1
2 kilograms of freeze dry powder of fermented soybean are weighed, 1.5 kilograms of gadol extract, 0.5 kilogram of hirudin, 0.3 kilogram of pheretima, is washed respectively
Only, it dries, adds water to cook 3 times, the 1st time amount of water is 35 kilograms, is decocted 3 hours, decoction liquor out of oozing；2nd time amount of water is
It 25 kilograms, decocts 3 hours, decoction liquor out of oozing；3rd time amount of water is 25 kilograms, is decocted 1 hour, decoction liquor out of oozing；Merge 3 times
Decoction liquor, filtration is concentrated into the medicinal extract that relative density at 25 DEG C is 1.20~1.30；1.1 kilograms of dextrin is added later,
It is uniformly mixed, dry, crushing is packed into capsule and health care product, every 0.3~0.5g of loading is made.
Above-mentioned raw materials are purchased from Xi'an Sen Fu Biotechnology Co., Ltd.
Embodiment 2
Weigh 2 kilograms of freeze dry powder of fermented soybean, 1.5 kilograms of gadol extract, 0.5 kilogram of hirudin, 0.3 kilogram of pheretima, folic acid 0.2
Kilogram, 0.3 kilogram of Radix Salviae Miltiorrhizae, 0.5 kilogram of wilsonii, 0.5 kilogram of ginkgo, 0.2 kilogram of neuropeptide, 0.5 kilogram of red yeast rice, safflower
0.8 kilogram.It cleans, dries respectively, add water to cook 3 times, the 1st time amount of water is 60 kilograms, is decocted 3 hours, decoction liquor out of oozing；
2nd time amount of water is 45 kilograms, is decocted 3 hours, decoction liquor out of oozing；3rd time amount of water is 45 kilograms, decocts 1 hour, oozes out
Decoction liquor；Merge 3 decoction liquors, filtration is concentrated into the medicinal extract that relative density is 1.20~1.30 at 25 DEG C；1 is added later
Kilogram dextrin, be uniformly mixed, it is dry, crush, it is tabletted.
Embodiment 3
So-and-so is tried to gain, male 74 years old, lives Liaoning Fuxin, 2008 annual tests check in cerebral infarction, and the sequelae that cerebral infarction leaves has a meal and stays rice
Grain, slobbers, does not slobber after taking functional nutrient food of the present invention, having a meal can take care of oneself.
Embodiment 4
Slowly so-and-so, female 63 years old, lives Dandong, check lacunar match, saliva stream is more than, hangs water in hospital 15 days not
It gets better standard, took functional nutrient food of the present invention later, and do not slobbered, memory is restored.
Embodiment 5
Ma, female live Shanghai Yangpu District, and cerebral infarction is matched 22 days, and pupil amplification was revived later, cannot eat cannot drink it is inactive,
Took functional nutrient food of the present invention later, freedom of movement, physical recovery is fine.
Embodiment 6
Gold so-and-so, male, 79 years old, live Shanghai, functional nutrient food of the present invention is taken in brain severe depletion of oxygen, and memory is obvious
Restore, it is no longer drowsiness.
Claims (4)
1. a kind of functional nutrient food for improving cardiovascular and cerebrovascular health status, which is characterized in that it includes following parts by weight
Effective active composition raw material: 20 parts of freeze dry powder of fermented soybean, 15 parts of gadol extract, 5 parts of hirudin, 3 parts of pheretima.
2. functional nutrient food according to claim 1, which is characterized in that it also include following parts by weight effective active at
Point raw material: 2 parts of folic acid, 3 parts of Radix Salviae Miltiorrhizae, 5 parts of wilsonii, 5 parts of ginkgo, 2 parts of neuropeptide, 5 parts of red yeast rice, 8 parts of safflower.
3. functional nutrient food according to claim 1 or 2, which is characterized in that it includes to account for medicinal material total weight
The auxiliary material of 10%~20% parts by weight, the auxiliary material can be cereal starch or potato starch or dextrin.
4. functional nutrient food according to claim 3, which is characterized in that each raw material is made of routine fashion
Tablet, capsule, oral solution or beverage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910733483.9A CN110368487A (en) | 2019-08-09 | 2019-08-09 | A kind of functional nutrient food improving cardiovascular and cerebrovascular health status |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910733483.9A CN110368487A (en) | 2019-08-09 | 2019-08-09 | A kind of functional nutrient food improving cardiovascular and cerebrovascular health status |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110368487A true CN110368487A (en) | 2019-10-25 |
Family
ID=68258738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910733483.9A Pending CN110368487A (en) | 2019-08-09 | 2019-08-09 | A kind of functional nutrient food improving cardiovascular and cerebrovascular health status |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110368487A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113368223A (en) * | 2020-02-25 | 2021-09-10 | 张旺凡 | A Chinese medicinal compound dispersible tablet for preventing and treating cardiovascular and cerebrovascular diseases, and its preparation method |
| CN113559208A (en) * | 2021-08-27 | 2021-10-29 | 浙江天真健康科技有限公司 | A Chinese medicinal composition for protecting cardiovascular and cerebrovascular diseases, and its preparation method |
| CN114246917A (en) * | 2022-02-28 | 2022-03-29 | 深圳德荫堂生物科技有限公司 | Biological medicament for relieving cardiovascular and cerebrovascular diseases and production method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103393114A (en) * | 2013-08-06 | 2013-11-20 | 西藏月王生物技术有限公司 | Lipid-lowering heart-nourishing immunity-enhancing preparation using highland barley monascus as main raw material and preparation method thereof |
| CN105796625A (en) * | 2014-12-31 | 2016-07-27 | 北京北大维信生物科技有限公司 | Pharmaceutical composition containing red yeast rice and safflower and preparation thereof |
| CN108125091A (en) * | 2018-01-22 | 2018-06-08 | 斯汏克（北京）生物科技有限公司 | A kind of preparation method for improving cardiovascular and cerebrovascular Chinese herbal medicine composite enzyme drink |
| CN109200279A (en) * | 2018-10-26 | 2019-01-15 | 路领群 | A kind of pharmaceutical composition of thrombus, anticoagulant |
| CN109393494A (en) * | 2018-10-25 | 2019-03-01 | 丽睿客信息科技（北京）有限公司 | A kind of person in middle and old age's health-care food composition and its application |
-
2019
- 2019-08-09 CN CN201910733483.9A patent/CN110368487A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103393114A (en) * | 2013-08-06 | 2013-11-20 | 西藏月王生物技术有限公司 | Lipid-lowering heart-nourishing immunity-enhancing preparation using highland barley monascus as main raw material and preparation method thereof |
| CN105796625A (en) * | 2014-12-31 | 2016-07-27 | 北京北大维信生物科技有限公司 | Pharmaceutical composition containing red yeast rice and safflower and preparation thereof |
| CN108125091A (en) * | 2018-01-22 | 2018-06-08 | 斯汏克（北京）生物科技有限公司 | A kind of preparation method for improving cardiovascular and cerebrovascular Chinese herbal medicine composite enzyme drink |
| CN109393494A (en) * | 2018-10-25 | 2019-03-01 | 丽睿客信息科技（北京）有限公司 | A kind of person in middle and old age's health-care food composition and its application |
| CN109200279A (en) * | 2018-10-26 | 2019-01-15 | 路领群 | A kind of pharmaceutical composition of thrombus, anticoagulant |
Non-Patent Citations (1)
| Title |
|---|
| 傅欣彤等: "HPLC法测定复方红景天胶囊中红景天苷和紫丁香苷的含量", 《药物分析杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113368223A (en) * | 2020-02-25 | 2021-09-10 | 张旺凡 | A Chinese medicinal compound dispersible tablet for preventing and treating cardiovascular and cerebrovascular diseases, and its preparation method |
| CN113559208A (en) * | 2021-08-27 | 2021-10-29 | 浙江天真健康科技有限公司 | A Chinese medicinal composition for protecting cardiovascular and cerebrovascular diseases, and its preparation method |
| CN114246917A (en) * | 2022-02-28 | 2022-03-29 | 深圳德荫堂生物科技有限公司 | Biological medicament for relieving cardiovascular and cerebrovascular diseases and production method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110368487A (en) | A kind of functional nutrient food improving cardiovascular and cerebrovascular health status | |
| US9937198B2 (en) | Multi-functional composition and preparation method and application thereof | |
| CN112999261B (en) | Natto fermented composition capable of relieving arteriosclerosis and preparation method and application thereof | |
| CN108653539A (en) | A kind of reduction uric acid integration of drinking and medicinal herbs tabletting and preparation method thereof | |
| CN109745359A (en) | Be conducive to keep blood glucose balance and prevent diabetes and its composition of complication and preparation method thereof | |
| CN108095113A (en) | A kind of composition, preparation and its application with fat reducing blood sugar reducing function | |
| KR102189416B1 (en) | Composition for preventing obesity and reducing body fat comprising complex extracts of Inula japonica | |
| CN104206955A (en) | Lycium ruthenicum tablet for reducing blood fat | |
| CN101473943B (en) | Health-care food for improving memory function and preparation method thereof | |
| CN101961367B (en) | Chinese medicinal composition for preventing alcoholic liver injury | |
| CN104758404B (en) | A kind of three snake compound powder of compound and preparation method thereof | |
| CN109395028A (en) | A kind of Ge Jingjia ginseng wine formula and preparation method preventing, treating three high diseases | |
| CN1927223A (en) | Fat-reducing and beauty nourishing capsule | |
| EP3616697A1 (en) | Use of a pharmaceutical carrier in the preparation of an anti-diabetic pharmaceutical composition | |
| KR101517836B1 (en) | A composition for the treatment of atherosclerosis comprising the red ginseng complex | |
| CN103766885A (en) | Health food for alleviating physical fatigue | |
| CN107088206B (en) | Preparation method and application of cortex mori extract | |
| CN105076614A (en) | Weight-reducing health protection tea | |
| CN104982762B (en) | A kind of garlic polysaccharide piece and preparation method thereof | |
| CN108379455B (en) | Uric acid reducing composition | |
| CN107411062A (en) | Matrimony vine weight reducing ferment | |
| CN103054906A (en) | Propolis ethanol extract for alleviating hangover and preparation method thereof, and application of propolis ethanol extract in producing buccal tablets | |
| KR20180079920A (en) | Composition for preventing, improving or treating hepatic fibrosis or liver cirrhosis comprising Cuscuta Semen extract | |
| CN103251743B (en) | Formulation for enhancing immunity, improving cardiovascular function and delaying senescence | |
| CN106109951A (en) | Prevent and treat medicine of hyperglycemia, hyperlipidemia, hypertension and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191025 |